Document:

Exhibit
10.8

 

TALENT
ENDORSEMENT AGREEMENT

 

THIS
SUPPLEMENTAL AGREEMENT is made as of this _____ day of ______________ 2013 by and between Tigrent Learning UK Limited of Boston
House, 69 — 75 Boston Manor Road, Brentford, Middlesex, TW8 9.1J (“Company”) and Celebrity Speakers of 90 High
Street, Burnham, Buckinghamshire, SL1 7JT (“CSA”) agent for Robbie Fowler (“Talent”) in his individual
capacity or his duly appointed Representative (collectively the “Parties”).

 

WITNESSETH:

 

WHEREAS,

 

		1.	Talent
                                         is currently a well-known public figure;

 

		2.	Company
                                         has entered into an agreement dated 2nd November 2012 with CSA (“Primary Agreement”)
                                         to engage the services of the Talent to endorse the Company’s new property training
                                         course “Property Academy” (“Property Training Course”) to be
                                         launched in 2013 as specified in clause 5 of the schedule to the Primary Agreement.

 

		3.	Company
                                         is engaged in developing, creating and providing educational training, products and materials
                                         related to real estate, securities and options trading and investment, as well as general
                                         wealth building and investing strategies, principles and motivation.

 

		4.	It
                                         is hereby acknowledged by the Parties that the Company is desirous of acquiring the right
                                         and license to utilize Talent’s name and brand, likeness and image to endorse by
                                         way of advertisement, promotion, and sale of a new property training brand (“Property
                                         Academy”) to be launched by the Company and as defined in this Agreement and Talent
                                         is willing to grant such right and license as herein below provided.

 

NOW,
THEREFORE, in consideration of the mutual covenants set forth herein and for other good and valuable consideration, it is
agreed as follows:

 

		1.	DEFINITIONS

 

The
following meanings shall apply to this agreement:

 

		1.	“Commencement
                                         Date” means: 1st January 2013.

 

		2.	“Materials”
                                         means: Power Point Presentations, Marketing Collaterals, Banners, Workbooks, Flyers or
                                         any other physical item required for the promotion and delivery of the Company’s
                                         new Property Training Course “Property Academy”.

 

		3.	“Product”
                                         means: The products and materials the Company develops, creates or provides in connection
                                         with its educational training, products and materials relating to the Property Training
                                         Course.

 

		4.	“Property”
                                         means: Talents name, initials, facsimile signature, photograph, video or images, likeness
                                         or other such pre-approved copy.

 

    	 

    	 

    

 

		5.	“Property
                                         Training Course” means: the property training course developed or to be developed
                                         by the Company to be called and marketed under the name/brand “Property Academy”
                                         or any other such name as agreed by the Parties.

 

		6.	“Territory”
                                         means: United Kingdom.

 

		7.	“Term”
                                         means: 1.5t January 2013 to 315t December 2013 or until terminated under the provisions
                                         of this Agreement or the Primary Agreement.

 

		2.	GRANT
                                         OF RIGHTS

 

Subject
to the terms and conditions and in consideration of the payments set forth herein and in the Primary Agreement, CSA as disclosed
agent for Talent grants to Company from the Commencement Date the right and license during the Term of this Agreement in the Territory
to use the “Property” in connection with the advertisement, promotion, and sale of the Property Training Course and
the Product as well as the right to use such Property on the Product and related packaging. The above license grant shall apply
to all material objects of the Property, in which the Property is fixed by any method now known or later developed, and from which
the Property can be perceived, reproduced, or otherwise communicated, either directly or with the aid of a machine or device.
The parties further understand and agree that Company hereby reserves the right to display its copyright notice on advertisements,
promotions or other materials as well as all Product, no matter what form or media, containing the Property subject always to
all and any copyright or other interests of the Talent.

 

CSA
on behalf of Talent further grants and assigns to Company the right to enforce applicable copyright and intellectual property
laws against third party infringers or malfeasors on Talent’s behalf or in Talent’s name.

 

		2A.	ADDITIONAL
                                         DUTIES AND PUBLIC APPEARANCES

 

In
accordance with the Primary Agreement, the Talent agrees that during the Term, he will make public appearances at the request
of the Company, to include appearing at Company events and/or participating in photo shoots as requested by Company, not to exceed
more than four such appearances or photo shoots per calendar year. Any public appearance and/or photo shoot must be approved by
the Talent prior to his agreement to attend, which shall not be unreasonably withheld providing the Talent does not have any prior
professional or other commitments and reasonable and adequate notice is given and received by CSA on behalf of Talent. The parties
agree that Company will pay any necessary and reasonable travel and lodging expenses incurred by Talent in making such requested
appearances as per “part 1” of the Primary Agreement.

 

		3.	TERM

 

This
Agreement shall be effective as of the date of execution by both parties. The period of license granted shall be for the Term
and shall extend for a period of twenty four (24) months or until terminated as per clause 8 herein. It is agreed that the Term
may be extended upon mutual agreement between the parties.

 

    	2

    	 

    

 

		4.	COMPENSATION

 

In
consideration for the licenses granted hereunder, Company agrees to pay to CSA as follows:

 

		a.	A
                                         [***]in the amount of [***]of Company’s revenues from sales of the Property Training
                                         Course and all Products after deductions for VAT, returns, refunds

 

		b.	Company
                                         shall be responsible for the tracking of sales of the Property Training Course and all
                                         Products containing the Property and providing to CSA:

 

		i.	A
                                         monthly list of the sales of Property Training Course and Product (with supporting sales
                                         prices and reconciled reports).

 

		ii.	Payment
                                         to CSA no later than thirty (30) days after receipt of invoice from CSA. CSA shall submit
                                         invoice to the Company no later than thirty (30) days after Company provides CSA with
                                         the list of the sales of Product (containing the Property with such supporting information
                                         that may be required or requested to be disclosed).

 

		c.	CSA
                                         shall have the right to request an independent audit of the sales of the Product containing
                                         the Property which the Company agrees to assist within a reasonable period of time of
                                         such request.

 

		5.	REVIEW
                                         OF MATERIALS

 

		a.	Talent
                                         shall have the right of approval in respect of all Product being proposed as any part
                                         of the Property appearing or integrated into it and all proposed use of the Property
                                         (including to whom the Property is distributed for sale if other than the general public)
                                         prior to public release and distribution.

 

		b.	All
                                         Materials or any part thereof shall be sent by the Company to CSA for approval by Talent.

 

		c.	Talent
                                         shall have seven (7) days following receipt of such Materials or any part thereof displaying
                                         the intended use of the Property to review and for CSA to provide to Company written
                                         approval for such use.

 

		d.	In
                                         the event that Talent objects to the Products or any part thereof and/or any proposed
                                         use of the Property, CSA on behalf of Talent shall submit to Company, within seven (7)
                                         days following Company’s official submission of materials, a written request for
                                         revisions. Talent shall not make any request for unreasonable revisions and shall not
                                         withhold consent for any proposed use of the Property unreasonably.

 

		e.	In
                                         the event that Talent does not provide either written approval of materials or a written
                                         request for revisions of such materials containing a proposed use of the Property within
                                         ten (10) days following Company’s submission of such materials to Talent for review,
                                         such non-response shall automatically be deemed to be an acceptance and approval of the
                                         proposed use of the Property.

 

    	3

    	 

    

 

		6.	RESERVATION
                                         OF RIGHTS

 

		a.	Subject
                                         to the terms of this Agreement, Talent shall retain all rights in and to his name and
                                         in the Property, his right of publicity, and the endorsement and, whether during the
                                         Term or any extension thereof, Talent shall not be prevented from using, permitting,
                                         or licensing by whatever means ,others to use his name or endorsement in connection with
                                         the advertisement, promotion, and sale of any product or service other than the Product
                                         or those that are substantially similar to the Product, including but not limited to
                                         all real estate, securities and/or options trading and investment educational trainings,
                                         products, materials. Company and Talent agree that they shall take all necessary steps
                                         during the Term to protect the endorsement in connection with the advertisement, promotion,
                                         and sale of the Product, subject always to the Company bearing any costs or liabilities
                                         in taking such steps and fully indemnifying the Talent and his agent in respect thereof.

 

		b.	It
                                         is understood and agreed that Talent shall retain all copyright and all other rights,
                                         title, and interest in the Property, including his likeness, name, and/or trademarks,
                                         where applicable, except as licensed hereunder.

 

		c.	Subject
                                         to the terms of this Agreement and in particular 5 above, it is understood and agreed
                                         that Company shall retain all right, title, and interest, including but not limited to
                                         all copyright interest, in and to the Product and any advertising or marketing collateral
                                         and/or materials created utilizing the Property under the license granted herein. The
                                         Company agrees to defend and fully indemnify the Talent and/or his agents in respect
                                         of such rights retained by the Company.

 

		d.	The
                                         parties agree to execute any documents reasonably requested by the other party to affect
                                         any of the above provisions. The Company agrees to defend and fully indemnify the Talent
                                         and/or his agents of any costs that may be incurred in complying with this provision.

 

		7.	REPRESENTATIONS,
                                         WARRANTIES AND INDEMNITY

 

		a.	Talent
                                         represents and warrants that he has not granted nor will he grant to any other party
                                         any right, permission, or license to use the Property in connection with the advertisement,
                                         sale, or promotion of the Product or in connection with products that are identical or
                                         substantially similar to the Product.

 

		b.	Talent
                                         further represents and warrants to Company that he has the full right, power, and authority
                                         to grant the Property herein.

 

		c.	Talent
                                         further represents and warrants that he has not misrepresented or concealed anything
                                         with respect to his background that may have a prejudicial effect on the value of the
                                         endorsement, that he is in good health, and that he has not engaged nor will he engage
                                         during the Term of this Agreement in any activity (criminal or otherwise) that could
                                         potentially have a negative impact on the Product.

 

    	4

    	 

    

 

		d.	Company
                                         agrees to defend, indemnify, and hold Talent harmless against all costs, expenses, and
                                         losses (including reasonable attorney fees and costs) incurred through claims of third
                                         parties against Talent based on the manufacture or sale of the Product including, but
                                         not limited to, actions founded on product liability.

 

		e.	Talent
                                         agrees to defend, indemnify, and hold Company, and its officers, directors, agents, and
                                         employees, harmless against all costs, expenses, and losses (including reasonable legal
                                         fees and costs) incurred through claims of third parties against Company based on a breach
                                         by Talent of any representation and/or warranty made in this Agreement or with respect
                                         to any third-party claims for infringement involving the use of the Property by Company.

 

		8.	TERMINATION

 

		a.	Except
                                         as provided in this Section 8, this Agreement shall terminate immediately upon the earlier
                                         of (i) the Term of this Agreement or (ii) dissolving of Company and/or Company’s
                                         complete cessation of doing all business.

 

		b.	Either
                                         party shall have the right to terminate this Agreement immediately in the event that
                                         Talent or the Company does any of the following:

 

		i.	Engages
                                         in illegal, immoral, or criminal conduct resulting in a felony conviction;

 

		ii.	Misrepresents
                                         or conceals anything in their background that could be detrimental to the value of the
                                         endorsement being made;

 

		iii.	Engages
                                         in conduct contrary to the best interests of the other party;

 

		iv.	Engages
                                         in conduct that reasonably offends the sensitivities of a significant portion of the
                                         population; or

 

		v.	Engages
                                         in conduct that could bring the other party into public disrepute.

 

		c.	Either
                                         party may terminate this provision at any time during the Term, in the event either party
                                         is guilty of a material breach of this Agreement, having been given notice of such breach
                                         and the breach not being rectified within a reasonable period of time.

 

		9.	POST-TERMINATION
                                         RIGHTS

 

		a.	Talent
                                         agrees that Company shall, for a period of nine (9) months (Sell-Off Period) following
                                         the effective date of termination, have the right to continue to sell Product bearing
                                         the Property and/or utilize advertising materials and collateral bearing the Property.
                                         Such sales and use shall be made subject to all the provisions of this Agreement and
                                         in particular clause 4 hereof.

 

		b.	Upon
                                         the expiration or termination of this Agreement, all rights granted to Company under
                                         this Agreement shall forthwith terminate and immediately revert to Talent, and Company
                                         shall, following the completion of the Sell-Off Period discontinue all use of and reference
                                         to the Property.

 

    	5

    	 

    

 

		10.	RELATIONSHIP
                                         OF THE PARTIES

 

Nothing
contained in this Agreement shall be construed as establishing a partnership, or a joint venture relationship between Talent and
Company.

 

		11.	FORCE
                                         MAJEURE

 

Neither
party will be liable for, or will be considered to be in breach of or default under this Agreement on account of, any delay or
failure to perform as required by this Agreement as a result of any causes or conditions that are beyond such Party’s reasonable
control and that such Party is unable to overcome through the exercise of commercially reasonable diligence. If any force majeure
event occurs, the affected Party will give prompt written notice to the other Party and will use commercially reasonable efforts
to minimize the impact of the event.

 

		12.	NOTICES

 

Notice:
Each notice, request or demand given or required to be given pursuant to this Agreement shall be in writing and shall deemed sufficiently
given if both emailed and deposited in the United Kingdom mail, registered First Class, postage pre-paid, and addressed to the
address of the intended recipient set forth below, or to such other address as may be specified in this Agreement or in writing
by the parties and receipt shall be deemed if sent by (i) email on the same day if sent on a day open for business and (ii) post
on the second day from posting, open for business.

 

	If
    to Company	Name:	lain
    Edwards
	 	Address:	Tigrent
    Learning UK Ltd
	 	 	Boston
    House
	 	 	69
    — 75 Boston Manor Road
	 	 	Brentford
	 	 	Middlesex
	 	 	TW8
    9.1.1
	 	 	England
	 	Telephone:	02089
    966700
	 	Facsimile:	02089
    966701
	 	Email:	iainedwards@tiRrent.com
	 	 	 
	If
    to CSA	Name:	Sharon
    Bowler
	 	Address:
    	Celebrity
    Speakers Ltd
	 	 	90
    High Street Burnham
	 	 	Buckinghamshire
	 	 	SL1
    7JT England
	 	Telephone:	01628
    601400
	 	Facsimile:	01628
    601401
	 	Email:	Sharon@speakers.co.uk
	 	 	 
	If
    to Talent	Name:	Robbie
    Fowler
	 	Address:	c/o
    Celebrity Speakers Ltd — As above

 

    	6

    	 

    

 

		13.	JURISDICTION/DISPUTES

 

This
Agreement shall be deemed to have been made in England. This Agreement shall be governed by the laws of England and Wales, and
all actions brought hereunder whether at law or in equity shall be brought in England. The parties hereby agree that any and all
claims arising from or in connection with the subject matter of this Agreement must be brought in England before the County Court
or High Court.

 

		14.	AGREEMENT
                                         BINDING ON SUCCESSORS

 

The
provisions of the Agreement shall be binding upon and shall inure to the benefit of the Parties hereto, their heirs, administrators,
successors and assigns.

 

		15.	ASSIGNABILITY

 

The
Parties may not assign this Agreement or the rights and obligations hereunder to any third party without the prior express written
approval of the other Party.

 

		16.	WAIVER

 

No
delay, failure or waiver by either party to exercise any right or remedy under this Agreement, and no partial or single exercise,
will operate to limit, preclude, cancel, waive or otherwise affect such right or remedy, nor will any single or partial exercise
limit, preclude, impair or waive any further exercise of such right or remedy or the exercise of any other right or remedy.

 

		17.	SEVERABILITY

 

If
any term, clause or provision hereof is held invalid or unenforceable by a court of competent jurisdiction, such invalidity shall
not affect the validity or operation of any other term, clause or provision and such invalid term, clause or provision shall be
deemed to be severed from the Agreement.

 

		18.	SURVIVAL

 

The
parties’ rights and obligations under the Primary Agreement and Articles 4, 6, 7, 9, 10, 12, 13, 14, and 15 shall survive
any expiration or earlier termination of this Agreement.

 

    	7

    	 

    

 

		19.	HEADINGS

 

All
section and subsection headings contained in this Agreement are for convenience only and shall not be deemed to constitute a part
of this Agreement nor affect the meaning of same.

 

		20.	NO
                                         DRAFTER

 

Both
parties warrant and represent that each have had equal input in drafting this Agreement and have had the opportunity to consult
with independent legal counsel.

 

		21.	EXPENSES

 

Bar
those covered in clause 1A, each party shall bear all expenses incidental to the performance of its obligations under this Agreement.

 

		22.	SEPARATE
                                         COUNTERPARTS

 

This
Agreement may be executed in several counterparts, each of which shall be an original but all of which together shall constitute
one and the same instrument.

 

		23.	ENTENT
                                         OF AGREEMENT

 

This
Agreement is subject to the terms of the Primary Agreement and both agreements supersede any and all other agreements, either
verbal or in writing between the parties hereto with respect to the use of Talent’s Property by Company, and contains all
of the covenants and agreements between the parties with respect to such use in any manner whatsoever providing that the terms
of the Primary Agreement shall remain effective at all times and such terms shall take precedence in the event of any conflict
between the terms. Each party to this Agreement acknowledges that no representation, inducements, promises, or agreements, verbally
or otherwise, have been made by any party, or anyone acting on behalf of any party, which are not embodied herein, and that no
other agreement, statement, or promise not contained in this Agreement shall be valid or binding on either party, other than as
expressed in the Primary Agreement and any other written agreement dated concurrent with or after this Agreement shall be valid
as between the signing parties thereto provided always such agreement does not override or conflict with the terms of the Primary
Agreement.

 

IN
WITNESS WHEREOF, the Parties hereto, intending to be legally bound hereby, have each caused to be affixed hereto its or his/her
hand and seal the day indicated.

 

	COMPANY	 	CSA
    on behalf of TALENT
	Tigrent
    Learning UK Limited	 	 
	 	 	 
	lain
    Edwards (authorized signatory)	 	Sharon
    Bowler (authorized signatory)
	 	 	 
	Date	 	Date

 

 

8EX-4.14

 Exhibit 4.14 

SECOND AMENDMENT TO FACILITY AGREEMENT 

SECOND AMENDMENT TO FACILITY AGREEMENT (this “Amendment”), dated as of August 11, 2014, by and among MANNKIND
CORPORATION, a Delaware corporation (the “Borrower”), DEERFIELD PRIVATE DESIGN FUND II, L.P. (“DPDF”) and DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P. (together with DPDF collectively referred to as the
“Purchasers” and together with the Borrower, the “Parties”). 
 RECITALS: 

A. Borrower and Purchasers have entered into that certain Facility Agreement dated as of July 1, 2013, as amended by that the First
Amendment to Facility Agreement and Registration Rights Agreement, dated as of February 28, 2014 (as the same may be amended, modified, restated or otherwise supplemented from time to time, the “Facility Agreement”). 

B. In connection with the Borrower’s proposed entry into (i) that certain License and Collaboration Agreement with Sanofi-Aventis
Deutschland GmbH (“Sanofi”), Technosphere International C.V., a wholly-owned subsidiary of the Borrower (“TICV”), and MannKind Netherlands BV, a wholly-owned subsidiary of TICV (“MNBV” and,
collectively with TICV, “Borrower Subsidiaries”), relating to Borrower’s Afrezza® rapid-acting inhaled insulin product (the “License Agreement”),
(ii) that certain Supply Agreement with Sanofi related to such product (the “Supply Agreement” and, together with the License Agreement, the “Collaboration Agreements”), and (iii) that certain loan
commitment letter with Sanofi regarding a loan facility to be made available by Sanofi to the Borrower in connection with the Collaboration Agreements, a copy of which is attached hereto as Exhibit A (the “Commitment Letter”)
pursuant to a loan agreement and related loan documents to be entered into by the Borrower and Sanofi after entry into the Collaboration Agreements and prior to the time the Collaboration Agreements become effective (the “Loan
Documents”), the Parties desire to amend the Facility Agreement to permit the incurrence by the Borrower of additional indebtedness and liens securing such indebtedness contemplated by the Commitment Letter and the Loan Documents, on the
terms set forth herein. 
 NOW, THEREFORE, in consideration of the mutual agreements contained herein, the Parties agree as follows: 

1. Defined Terms. Capitalized terms used herein which are defined in the Facility Agreement, unless otherwise defined herein, shall have
the meanings ascribed to them in the Facility Agreement. The Recitals to this Amendment are incorporated herein in their entirety by this reference thereto. 

2. Amendments to Facility Agreement. Upon the satisfaction of the conditions set forth in Section 3 of this Amendment: 

a. Section 1.1 of the Facility Agreement is hereby amended to add the following additional defined terms: 

  
 1 

 “Collaboration Agreements” shall have the meaning provided
therefor in the Second Amendment. 
 “Commitment Letter” shall have the meaning provided therefor in the
Second Amendment. 
 “Intercreditor Agreement” means an Intercreditor Agreement in form and substance
reasonably acceptable to Purchasers and consistent with the terms set forth in Exhibit B to the Second Amendment, among Borrower, Purchasers and Sanofi or its affiliate providing the loans to Borrower under the Loan Documents. 

“Loan Documents” shall have the meaning provided therefor in the Second Amendment. 

“Sanofi” shall have the meaning provided therefor in the Second Amendment. 

“Second Amendment” means the Second Amendment to Facility Agreement dated as of August 11, 2014 between
Borrower and Purchasers. 
 b. The defined term “Permitted Indebtedness” in Section 1.1 of the Facility Agreement is
amended to renumber subsection “(xxvi)” as “(xxvii)” and insert a new subsection (xxvi) to read as follows: 

“(xxvi) Indebtedness to Sanofi or its affiliates incurred in connection with the transactions contemplated by the Collaboration
Agreements, the Commitment Letter and the Loan Documents (which shall be consistent with the terms set forth in the Commitment Letter) in an aggregate principal amount of up to One Hundred Seventy-Five Million Dollars ($175,000,000) plus any PIK
interest that may be accrued and added to such principal that (a) may be secured (i) on a first lien basis by Insulin Inventory located in the United States, and the property and improvements located at 28903 North Avenue Paine,
Valencia, CA, and (ii) on a second lien basis by all other Collateral pursuant to the Intercreditor Agreement, and (b) may be prepaid at any time (x) with distributions allocable to Borrower under the Collaboration Agreements, or
(y) with any other funds of Borrower if, Borrower first offers to prepay the Obligations in the amount of the proposed prepayment to Sanofi, and Purchasers decline such prepayment; and”. 

c. The defined term “Permitted Liens” in Section 1.1 of the Facility Agreement is amended to renumber subsection
“(xxvi)” as “(xxvii)” and insert a new subsection (xxvi) to read as follows: 
 “(xxvi) Liens securing
Indebtedness permitted by clause (xxvi) of the definition of Permitted Indebtedness with the priority set forth therein; and”. 

3. Conditions Precedent. The effectiveness of this Amendment is subject to the following conditions precedent: 

  
 2 

 a. Delivery of Documents. The Borrowers and the Purchasers shall each execute and deliver
this Amendment. 
 b. Performance; No Default. The Borrower shall have performed and complied with all agreements and conditions
contained in the Facility Agreement and the other Transaction Documents to be performed by or complied with by the Borrower prior to the date hereof in all material respects. 

4. Representations and Warranties. The Borrower hereby represents and warrants to Purchasers as follows: 

a. As of the date hereof, the representations and warranties of the Borrower contained in the Transaction Documents are (i) in the case of
representations and warranties qualified by “materiality,” “Material Adverse Effect” or similar language, true and correct in all respects and (ii) in the case of all other representations and warranties, true and correct in
all material respects, in each case on and as of the date hereof, except to the extent that any such representation or warranty relates to a specific date, in which case such representation and warranty shall be true and correct in all respects or
all material respects, as applicable, as of such earlier date; 
 b. The execution, delivery and performance by the Borrower of this
Amendment (i) are within the Borrower’s corporate powers, (ii) have been duly authorized by all necessary action pursuant to its Organizational Documents, (iii) require no further action by or in respect of, or filing with, any
Government Authority, and (iv) do not violate, conflict with or cause a breach or a default under any provision of applicable law or regulation or of Borrower’s Organizational Documents or of any agreement, judgment, injunction, order,
decree or other instrument binding upon Borrower, except to the extent such violation, conflict, breach or default would not individually or in the aggregate reasonably be expected to have a Material Adverse Effect; 

c. This Amendment constitutes the valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms,
except as enforceability may be limited by applicable bankruptcy, insolvency, or similar laws relating to the enforcement of creditor’s rights generally and by general equitable principles; and 

d. Subject to the effectiveness of this Amendment, no Event of Default exists. 

5. No Further Amendments; Ratification of Liability. Except as amended hereby, the Facility Agreement and each of the other Transaction
Documents shall remain in full force and effect in accordance with their respective terms. Borrower as debtor, grantor, pledgor, guarantor or assignor, or in any similar capacity in which it has granted Liens or acted as an accommodation party or
guarantor, as the case may be, hereby ratifies, confirms and reaffirms its liabilities, its payment and performance obligations (contingent or otherwise) and its agreements under the Facility Agreement and the other Transaction Documents, all as
amended by this Amendment, and the liens and security interests granted, created and perfected thereby. The Purchasers’ agreement to the terms of this Amendment or any other amendment of the Facility

  
 3 

 
Agreement or any other Transaction Document shall not be deemed to establish or create a custom or course of dealing among Borrower, Purchasers, Assignees, or any of them. This Amendment,
together with the other Transaction Documents, contains the entire agreement among Borrower and Purchasers contemplated by this Amendment. 

6. Covenants. Borrower covenants and agrees (i) not to enter into the Loan Documents unless and until Borrower and Sanofi enter
into the Intercreditor Agreement with Purchasers consistent with the terms set forth in Exhibit B attached hereto and (ii) to provide Purchasers with executed copies of all Loan Documents upon their execution. 

7. Incorporation by Reference. The provisions of Article 6 of the Facility Agreement are incorporated herein by reference mutatis
mutandis. 
 [Remainder of Page Intentionally Left Blank, signature page follows] 

  
 4 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date set forth above. 

 

			
	BORROWER:
	
	MANNKIND CORPORATION
		
	By:	 	 /s/ David Thomson

	Name:	 	David Thomson
	Title:	 	General Counsel
	
	PURCHASERS:
	
	DEERFIELD PRIVATE DESIGN FUND II, L.P.
		
	By:	 	Deerfield Mgmt., L.P., its General Partner
	By:	 	J.E. Flynn Capital, LLC, its General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory
	
	DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.
		
	By:	 	Deerfield Mgmt., L.P., its General Partner
	By:	 	J.E. Flynn Capital, LLC, its General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory

  
 5 

 EXHIBIT A TO SECOND AMENDMENT 

EXECUTION VERSION 
 HOECHST GMBH

 Industriepark Hoechst 

Gebäude K703 
 D-65926
Frankfurt am Main 
 PERSONAL AND CONFIDENTIAL 

August 11, 2014 
 MannKind Corporation 

28903 North Avenue Paine 
 Valencia, California 91355 

Attention: General Counsel 
 Commitment
Letter 
 Ladies and Gentlemen: 
 Reference is made to
the License and Collaboration Agreement dated as of August 11, 2014 (the “License Agreement”) by and among MannKind Corporation, a Delaware corporation (“MannKind”), Technosphere International C.V., a Dutch
limited partnership (“TICV” and, together with MannKind, the “Licensors”), and Sanofi-Aventis Deutschland GmbH, a company organized and existing under the laws of Germany (“Sanofi”). In connection
with the consummation of the transactions contemplated by the License Agreement you have requested that Hoechst GmbH (the “Lender”) provide a $175.0 million senior secured revolving credit facility (the “Facility”)
to MannKind (in such capacity, the “Borrower” or “you”) on the terms and subject to the conditions set forth in this Commitment Letter and Exhibit A (collectively, the “Commitment Letter”).

  

	1.	Commitments 

 The Lender is pleased to advise you of its commitment to provide to the Borrower the
Facility on the terms and subject to the conditions set forth in this Commitment Letter. 
  

	2.	Conditions Precedent 

 The Lender’s commitment hereunder is subject to the following conditions:
(i) the definitive loan documents relating to the Facility, including without limitation a credit agreement (or promissory note), security agreements and other related definitive documents (collectively, the “Loan Documents”)
shall have been prepared based upon and substantially consistent with the terms set forth in this Commitment Letter and otherwise reasonably satisfactory to the Lender and the Borrower and shall have been executed and delivered by the Borrower,
(ii) the Lender shall be reasonably satisfied that the Borrower has complied with all other customary closing conditions, including: (A) the delivery of customary corporate records and documents from public officials and officer’s
certificates; (B) evidence of authority; and (C) grant and perfection of liens on the collateral to secure the Facility, (iii) the accuracy of the representations and warranties specified in Exhibit A and (iv) the absence of any
default or event of default specified in Exhibit A. Notwithstanding the forgoing, the Borrower shall be required only to use commercially reasonable efforts to obtain account control agreements with its depository banks in form and substance
reasonably satisfactory to the Lender within 90 days after the Closing Date (as defined in 

  
 1 

 
Exhibit A) and a failure to obtain such account control agreements shall not result in a default provided the Borrower has used commercially reasonable efforts. 

 

	3.	Indemnification 

 You hereby agree to indemnify upon demand and hold harmless the Lender and each
partner, trustee, shareholder, director, officer, employee, advisor, representative, agent, attorney and controlling person thereof (each of the above, an “Indemnified Person”) from and against any and all actions, suits,
proceedings (including any investigations or inquiries), claims, losses, damages, liabilities or expenses (including legal expenses), joint or several, of any kind or nature whatsoever that may be brought or threatened by the Borrower, the
Guarantors (as defined in Exhibit A), any of their respective affiliates or any other person or entity and which may be incurred by or asserted against or involve any Indemnified Person (whether or not any Indemnified Person is a party to such
action, suit, proceeding or claim) arising solely from this Commitment Letter, the Facility, any other Loan Document or any use or intended use of the proceeds of the Facility other than those relating to the License Agreement; provided that
you will not have to indemnify an Indemnified Person against any claim, loss, damage, liability or expense to the extent the same resulted directly and primarily from (i) the gross negligence or willful misconduct of such Indemnified Person (to
the extent determined by a court of competent jurisdiction in a final and non-appealable judgment) and (ii) a material breach of the obligations of such Indemnified Person under this Commitment Letter (to the extent determined by a court of
competent jurisdiction in a final and non-appealable judgment). 
 Your indemnity and reimbursement obligations under this Section 3 will be in
addition to any liability which you may otherwise have and will be binding upon and inure to the benefit of the successors, assigns, heirs and personal representatives of you and the Indemnified Persons. 

Neither party nor any other Indemnified Person will be responsible or liable to the other party or any other person or entity for any indirect, special,
punitive or consequential damages which may be alleged as a result of this Commitment Letter, the Facility or any related transaction contemplated hereby or thereby or any use or intended use of the proceeds of the Facility; provided that
nothing in this paragraph shall limit your indemnity obligations hereunder. 
  

	4.	Assignments 

 This Commitment Letter may not be assigned by either party without the prior written
consent of the other party (and any purported assignment without such consent will be null and void), is intended to be solely for the benefit of the parties hereto and is not intended to confer any benefits upon, or create any rights in favor of,
any person (including either party’s equity holders, employees or creditors) other than the parties hereto (and any Indemnified Person). The Lender may assign its commitments and agreements hereunder, in whole or in part, to any of its
affiliates (other than to Sanofi-Aventis Deutschland GmbH). Notwithstanding the prior sentence, the parties agree that the Lender shall remain liable for the performance of its obligations hereunder in the case of an assignment by the Lender to any
of its affiliates. This Commitment Letter may not be amended or any term or provision hereof waived or modified except by an instrument in writing signed by each of the parties hereto. 

 

	5.	Waiver of Jury Trial; Governing Law; Submission to Jurisdiction; Surviving Provisions 

 ANY RIGHT TO
TRIAL BY JURY WITH RESPECT TO ANY ACTION, SUIT, PROCEEDING OR CLAIM ARISING IN CONNECTION WITH OR AS A RESULT OF ANY MATTER REFERRED TO IN THIS COMMITMENT LETTER IS HEREBY IRREVOCABLY WAIVED BY THE PARTIES HERETO. THIS COMMITMENT LETTER WILL BE
GOVERNED BY 

  
 2 

 
AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. Each of the parties hereto hereby irrevocably (i) submits, for itself and its property, to the exclusive
jurisdiction of (a) the Supreme Court of the State of New York, New York County, located in the Borough of Manhattan and (b) the United States District Court for the Southern District of New York and any appellate court from any such
court, in any action, suit, proceeding or claim arising out of or relating to this Commitment Letter the transactions related thereto or the performance of services contemplated hereunder, or for recognition or enforcement of any judgment, and
agrees that all claims in respect of any such action, suit, proceeding or claim may be heard and determined in such New York State court or such Federal court, (ii) waives, to the fullest extent permitted by law, any objection that it may now
or hereafter have to the laying of venue of any action, suit, proceeding or claim arising out of or relating to this Commitment Letter, the transactions related thereto or the performance of services contemplated hereunder in any such New York State
or Federal court and (iii) waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of any such action, suit, proceeding or claim in any such court. Each of the parties hereto agrees to commence
any such action, suit, proceeding or claim either in the United States District Court for the Southern District of New York or in the Supreme Court of the State of New York, New York County located in the Borough of Manhattan. 

This Commitment Letter is issued for the benefit of the parties hereto and no other person or entity may rely hereon (other than the Indemnified Persons).

 The provisions of Section 3 and this Section 5 of this Commitment Letter will survive any termination or completion of the arrangements
contemplated by this Commitment Letter, including without limitation whether or not the Loan Documents are executed and delivered and whether or not the Facility is made available or any loans under the Facility are disbursed; provided,
however, that, to the extent covered by the Loan Documents, your obligations under this Commitment Letter shall automatically terminate and be superseded by the corresponding provisions of the Loan Documents upon the effectiveness thereof.

  

	6.	Termination 

 Our commitments hereunder will terminate upon (i) the abandonment or termination of
the License Agreement in accordance with the last sentence of Section 15.16 of the License Agreement or (ii) the Lender’s receipt from you of written notice of termination of this Commitment Letter. 

This Commitment Letter may be executed in any number of counterparts, each of which when executed will be an original and all of which, when taken together,
will constitute one agreement. Delivery of an executed counterpart of a signature page of this Commitment Letter by facsimile or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof. 

[The remainder of this page is intentionally left blank.] 

  
 3 

 
			
	Very truly yours,
	
	HOECHST GMBH
		
	By:	 	  

	Name:	 	
	Title:	 	
		
	By:	 	  

	Name:	 	
	Title:	 	

 Commitment Letter 

 ACCEPTED AND AGREED TO AS OF THE DATE FIRST WRITTEN ABOVE: 

MANNKIND CORPORATION 
  

			
	By:	 	  

	Name:	 	
	Title:	 	

 Commitment Letter 

 Exhibit A 

Summary of Terms and Conditions of the Facility 

This Summary of Terms and Conditions outlines the material terms and conditions of the Facility. 

 

			
	Borrower:	  	MannKind Corporation (the “Borrower”).
		
	Guarantors:	  	The entities that are guarantors under that certain Facility Agreement dated as of July 1, 2013, by and among MannKind and the purchasers party thereto (as amended, restated, supplemented or otherwise modified from time to time,
the “Deerfield Facility”).
		
	Lender:	  	Hoechst GmbH (the “Lender”).
		
	Purpose/Use of Proceeds:	  	The proceeds of the Facility will be used to fund MannKind’s Sharing Percentage of any Losses (each as defined in the License Agreement) (the “Loss Amount”).
		
	Facility:	  	A $175.0 million senior secured revolving credit facility (the “Facility”).
		
	Availability:	  	Amounts available under the Facility may be borrowed, repaid and reborrowed after the Closing Date (as defined below) until the Maturity Date (as defined below); provided that, no amounts under the Facility may be borrowed
after the occurrence or during the continuance of an “Event of Default” under the Deerfield Facility that has resulted in the lender under the Deerfield Facility commencing enforcement proceedings with respect to its rights thereunder. The
Facility shall only be borrowed on a quarterly basis and each borrowing shall not exceed the Loss Amount for the fiscal quarter most recently ended. No Loss Amount may be carried forward to the next succeeding fiscal quarter.
		
	Closing Date:	  	The date on which the Loan Documents are executed in accordance with the Commitment Letter (the “Closing Date”) which in no event shall be later than the “Effective Date” as that term is defined in the
License Agreement (the “License Effective Date”).
		
	Maturity:	  	The maturity date (the “Maturity Date”) will be the tenth anniversary of the License Effective Date.
		
	Amortization:	  	None. Payable in full on the Maturity Date.
		
	Interest Rate:	  	All amounts outstanding under the Facility will bear interest at a rate per annum equal to 8.5% (2.06% per quarter compounded), and shall be paid-in-kind.
		
	Default Interest:	  	Upon the occurrence and during the continuance of any payment or insolvency event of default, interest will accrue at a rate of 2.0% per

  
 Exhibit A-1 

			
		  	annum plus the rate otherwise applicable thereto on any amount then outstanding and will be payable on demand.
		
	Interest Payments:	  	Quarterly; payable in-kind in arrears and computed on the basis of a 360-day year.
		
	Voluntary Prepayments:	  	The Facility may be prepaid in whole or in part upon 5 business day’s prior written notice without premium or penalty.
		
	Mandatory Prepayments:	  	The Borrower shall prepay the Facility in an amount equal to 100% of MannKind’s Sharing Percentage of any Profit (as defined in the License Agreement), payable no later than 30 days following the date of receipt;
provided that any voluntary prepayments made by the Borrower during the relevant quarter shall be credited against any amount payable as a result of MannKind’s Sharing Percentage of any Profit.
		
	Collateral:	  	The obligations of the Borrower and the Guarantors under the Facility will be secured by a perfected (x) first priority security interest in any insulin located in Danbury, CT owned by the Borrower and its subsidiaries and any
contractual rights and obligations pursuant to which the Borrower purchases or has purchased such insulin and (y) second priority security interest in all assets of the Borrower and the Guarantors required to be secured pursuant to the Deerfield
Facility; provided that the Lender shall have a first priority mortgage on the real property and improvements thereon located at 28903 North Avenue Paine, Valencia, California 91355; provided further that Lender agrees to
release the mortgage on the Valencia facility if the Valencia facility is sold as long as the net cash proceeds of such sale are used to prepay the loan under the Facility and the maximum limit available to be borrowed under the Facility is reduced
accordingly.
		
	Intercreditor Agreement:	  	The Lender and the lender under the Deerfield Facility shall agree to negotiate in good faith an intercreditor agreement reflecting the principles set forth in the attachment to the Intercreditor Principles Agreement dated as of
August 11, 2014, between the Lender and the lender under the Deerfield Facility.
		
	Representations and	  	
	Warranties:	  	The Facility will contain only the following representations and warranties by the Borrower and the Guarantors (subject to customary exceptions, baskets and thresholds to be agreed): organization, requisite power and authority,
qualification; due authorization; no conflict with any material agreements listed on the Borrower’s most recently filed annual report on Form 10-K or subsequent quarterly reports on Form 10-Q; any governmental consents related to the Loan
Documents; compliance with laws; binding obligation; adverse proceedings relating to any Loan Document or the performance by the Borrower or any Guarantor thereunder; payment of taxes; no defaults; solvency; and security
documents.

  
 Exhibit A-2 

			
		
	Covenants:	  	The Facility will contain only the following affirmative and negative covenants by the Borrower and the Guarantors (subject to customary exceptions, baskets and thresholds to be agreed and including, without limitation, any
exceptions, baskets or carve-outs included in the Deerfield Facility):
		
		  	Affirmative covenants: existence; payment of taxes and claims; compliance with laws; use of proceeds; notices; additional collateral; and further assurances.
		
		  	Negative covenants: indebtedness (which shall permit the Deerfield Facility and any refinancing thereof in an amount not to exceed $160,000,000 and shall include the ability to reborrow such amounts upon the conversion of
some or all of the existing indebtedness under the Deerfield Facility into equity); liens; and amendments or waivers of organizational documents in a manner that is materially adverse to the interest of the Lender.
		
	Events of Default:	  	The Facility will include only the following events of default (subject to customary exceptions, baskets, thresholds and cure periods to be agreed): failure to make payments when due; breach of certain covenants; breach of
representations; other defaults under Loan Documents; involuntary bankruptcy; voluntary bankruptcy; dissolution; failure to maintain the valid perfected security interest having the applicable priority purported to be granted under the security
documents, the failure of any other Loan Document to be a valid binding obligation of the parties thereto enforceable in accordance with its terms or the Borrower or any guarantor shall so state in writing; and termination of the License Agreement
by Sanofi as a result of a breach thereof by MannKind. For the avoidance of doubt the Loan Documents shall not contain a cross default to other indebtedness, including but not limited to the Deerfield Facility.
		
		  	In the event of any event of default mentioned above relating to the failure to make payments when due; breach of the negative covenants relating to the incurrence of indebtedness or creation of liens; involuntary bankruptcy;
voluntary bankruptcy; dissolution; failure to maintain the valid perfected security interest having the applicable priority purported to be granted under the security documents, the failure of any other Loan Document to be a valid binding obligation
of the parties thereto enforceable in accordance with its terms or the Borrower or any guarantor shall so state in writing; or termination of the License Agreement by Sanofi as a result of a breach by MannKind of the non-compete obligations in
Section 2.8(a) of the License Agreement; the Lender shall have the right but not the obligation to accelerate the amounts due under the Facility and cause the same to become immediately due and payable. In the event of any other event of default
listed above, the Lender’s remedy shall be to terminate the commitment to make additional loans to the Borrower but the Lender shall not have the right to accelerate the amounts outstanding
under

  
 Exhibit A-3 

			
		  	the Facility or to otherwise cause any such obligations to become due and payable prior to the Maturity Date.
		
	Conditions Precedent to	  	
	Closing Date:	  	The conditions set forth or referred to in Section 2 of the Commitment Letter.
		
	Indemnity and Expenses:	  	The Facility will provide customary and appropriate provisions relating to indemnity and related matters in a form acceptable to the Lender. The Borrower will also pay all out-of-pocket expenses of the Lender (including the
reasonable fees, disbursements and other charges of counsel) in connection with the enforcement of the Loan Documents or in any bankruptcy case or insolvency proceeding.
		
	Governing Law and	  	
	Jurisdiction:	  	New York.

  
 Exhibit A-4 

 EXHIBIT B TO SECOND AMENDMENT 

Intercreditor Principles Agreement 

Reference is made to (i) that certain Facility Agreement dated as of July 1, 2013 (as amended, restated, supplemented or otherwise modified from
time to time, the “Deerfield Facility”), by and among MannKind Corporation (“MannKind”) and the purchasers party thereto (the “Deerfield Lenders”) and (ii) that certain Commitment Letter dated
as of August 11, 2014 (the “Commitment Letter”), by and among Hoechst GmbH (the “Sanofi Lender”) and MannKind. 
 The
Deerfield Lenders and the Sanofi Lender hereby agree that (i) the Deerfield Lenders will have a first priority lien on all of the assets of MannKind and the other guarantors under the Deerfield Facility designated as collateral under the
Deerfield Facility (the “Deerfield Lenders’ First Lien Collateral”), (ii) (a) the Sanofi Lender will have a second priority lien on the Deerfield Lenders’ First Lien Collateral (the “Sanofi Lender’s
Second Lien Collateral”) and (b) the Sanofi Lender will have a first priority lien on (x) any insulin inventory located in the United States and (y) the real property of MannKind located in Valencia, CA (clauses (x) and
(y), the “Sanofi Lender’s First Lien Collateral”) and (iii) the Deerfield Lenders will have no lien on the Sanofi Lender’s First Lien Collateral. It is further agreed that the terms attached hereto as Exhibit A will
be incorporated into an intercreditor agreement between the Deerfield Lenders and the Sanofi Lender. 
 This Intercreditor Principles Agreement may be
executed in any number of counterparts, each of which when executed will be an original, and all of which, when taken together, will constitute one agreement. Delivery of an executed counterpart of a signature page of this Intercreditor Principles
Agreement by facsimile or other electronic transmission will be effective as delivery of a manually executed counterpart hereof. This Intercreditor Principles Agreement constitutes the entire contract between the parties hereto with respect to the
subject matter hereof and supersede all previous agreements and understandings, oral or written, with respect thereto. This Intercreditor Principles Agreement and the rights and obligations of the parties hereunder will be governed by and construed
in accordance with the laws of the State of New York without regard to conflict of law principles that would result in the application of any law other than the law of the State of New York. 

[The remainder of this page is intentionally left blank.] 

 Accepted and Agreed to as of August 11, 2014: 

DEERFIELD PRIVATE DESIGN FUND II, L.P. 
 By: Deerfield
Mgmt., L.P., its General Partner 
 By: J.E. Flynn Capital, LLC, its General Partner 

 

			
	By:	 	  

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory

 DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P. 

By: Deerfield Mgmt., L.P., its General Partner 
 By: J.E. Flynn
Capital, LLC, its General Partner 
  

			
	By:	 	  

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory

 Intercreditor Principles Agreement 

 HOECHST GmbH 
  

			
	By:	 	  

	Name:	 	
	Title:	 	
		
	By:	 	  

	Name:	 	
	Title:	 	

 Intercreditor Principles Agreement 

 Exhibit A 
  

	(i)	If a default has occurred under the Deerfield Facility and the Deerfield Lenders have accelerated their indebtedness, any payment or distribution of any character by or on behalf of MannKind, whether in cash, securities
or other property, that constitutes or is traceable to proceeds of the Deerfield Lender’s First Lien Collateral, that is received by the Sanofi Lender before the Obligations (as defined in the Deerfield Facility) to the Deerfield Lenders shall
have been paid in full in cash, shall be held in trust by the Sanofi Lender for the benefit of, and shall be paid over to the Deerfield Lenders, to the extent necessary to pay the Obligations due to them in full in cash. 

If a default has occurred under the loan provided by the Sanofi Lender to MannKind (such loan, the “Sanofi Loan”) and the
Sanofi Lender has accelerated its indebtedness, any payment or distribution of any character by or on behalf of MannKind, whether in cash, securities or other property, that constitutes or is traceable to proceeds of the Sanofi Lender’s First
Lien Collateral, that is received by the Deerfield Lenders before the obligations to the Sanofi Lender shall have been paid in full in cash, shall be held in trust by the Deerfield Lenders for the benefit of, and shall be paid over to the Sanofi
Lender, to the extent necessary to pay the obligations due to the Sanofi Lender in full in cash. 
  

	(ii)	Prior to the payment in full in cash of the Obligations to the Deerfield Lenders or the obligations to the Sanofi Lender, as the case may be, the Deerfield Lenders shall have the exclusive right (as between the
Deerfield Lenders and the Sanofi Lender) to manage, perform and enforce the terms of the Deerfield Facility with respect to the Deerfield Lenders’ First Lien Collateral, and the Sanofi Lender shall have the exclusive right (as between the
Deerfield Lenders and the Sanofi Lender) to manage, perform and enforce the terms of the loan documents related to the Sanofi Loan with respect to the Sanofi Lender’s First Lien Collateral, and each party shall have the exclusive right to
exercise and enforce all of their respective privileges and rights thereunder according to their sole discretion and the exercise of their sole business judgment, including the exclusive right to exercise all of their respective rights and remedies
as secured lenders under the UCC with respect to assets of MannKind on which they have first liens. 

  

	(iii)	 In the event of any voluntary or involuntary insolvency or bankruptcy proceedings, or any receivership, liquidation, reorganization or other similar
proceedings in connection therewith relative to MannKind or to its property, then (a) the Sanofi Lender shall be paid in full in cash from the proceeds of the Sanofi Lender’s First Lien Collateral in respect of all of the obligations due
to it from MannKind, including without limitation, any interest due and payable thereunder whether or not such interest is an allowed claim in such proceeding before the Deerfield Lenders are entitled to receive (whether directly or indirectly), or
make any demands for, any payment from the proceeds of the Sanofi Lender’s First Lien Collateral; and (b) the Deerfield Lenders shall be paid in full in cash from the proceeds of the Deerfield Lenders’ First Lien Collateral in respect
of all of the 

	 	
Obligations due to it from MannKind, including without limitation, any interest due and payable thereunder whether or not such interest is an allowed claim in such proceeding before the Sanofi
Lender is entitled to receive (whether directly or indirectly), or make any demands for, any payment from the proceeds of the Deerfield Lenders’ First Lien Collateral; 

 

	(iv)	The Sanofi Lender may not offer Debtor in Possession financing unless any such financing does not (a) provide for liens or claims that are senior or equal to the liens or adequate protection claims of the Deerfield
Lenders with respect to the Deerfield Lenders’ First Lien Collateral, (b) require a specific plan of reorganization or the sale of assets prior to a default, (c) require payment in cash upon plan confirmation the source of which, in
whole or in part, is the Deerfield Lenders’ First Lien Collateral unless the Obligations due to the Deerfield Lenders are first paid in full in cash or (d) have provisions that are otherwise inconsistent with terms of this term sheet.

 The Deerfield Lenders may not offer Debtor in Possession financing unless any such financing does not (a) provide for
liens or claims that are senior or equal to the liens or adequate protection claims of the Sanofi Lender with respect to the Sanofi Lender’s First Lien Collateral, (b) require a specific plan of reorganization or the sale of assets prior
to a default, (c) require payment in cash upon plan confirmation the source of which, in whole or in part, is the Sanofi Lender’s First Lien Collateral unless the obligations due to the Sanofi Lender are first paid in full in cash or
(d) have provisions that are otherwise inconsistent with terms of this term sheet. 
  

	(v)	The Sanofi Lender will not object to relief from stay or adequate protection requested by the Deerfield Lenders with respect to the Deerfield Lenders’ First Lien Collateral so long as any such adequate protection
does not provide for liens that are senior or equal to the liens or adequate protection claims of the Sanofi Lender with respect to the Sanofi Lender’s First Lien Collateral; 

The Deerfield Lenders will not object to relief from stay or adequate protection requested by the Sanofi Lender with respect to the Sanofi
Lender’s First Lien Collateral so long as any such adequate protection does not provide for liens that are senior or equal to the liens or adequate protection claims of the Deerfield Lenders with respect to the Deerfield Lenders’ First
Lien Collateral; 
  

	(vi)	The Sanofi Lender will not request relief from the stay with respect to their second lien on the Deerfield Lenders’ First Lien Collateral; 

 

	(vii)	Following (a) acceleration of the Deerfield Facility or (b) the commencement of a proceeding under the Bankruptcy Code or any other Federal, state or foreign bankruptcy, insolvency, receivership or similar law
by or against any grantor, the Sanofi Lender may request within 30 days thereof to purchase all, but not less than all, of the aggregate amount of the Deerfield Facility outstanding at the time of purchase at par; and 

 

	(viii)	The Deerfield Lenders and the Sanofi Lender will agree to additional terms as are appropriate and customary for an intercreditor agreement of this nature, including waivers of marshaling, appraisal, valuation and
similar rights and waiver of any claims under Sections 506(c) and 552 of the Bankruptcy Code.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]